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deﬁcient mice expand CD8 similar to w.t. mice. The combined knock 
out of B7.1 and B7.2 completely abrogates CD8 expansion while the 
loss of either of the single genes reduces expansion to about 50% of 
w.t. NKT cells are not required but NK cells enhance CD8 CTL re-
sponses. Antigen cross presentation and cross priming of cognate CD8 
cells is ~20 million fold enhanced when peptides are chaperoned by 
gp96 compared to their presence as intact protein, as measured with the 
ovalbumin TCR transgenic system.
Following the events after intraperitoneal injection of tumors secret-
ing gp96-Ig, we found that gp96-secretion promotes recruitment of 
monocyte/macrophages, dendritic cells and NK cells. DC and NK cells 
become activated only when gp96 is secreted by the injected tumor 
cells leading to local CD8 CTL expansion followed by systemic expan-
sion. Lymphotoxin-α k.o. mice have no peripheral lymph nodes includ-
ing mesenteric lymph nodes and Peyer’s patches, however they are able 
to support gp96-Ig mediated CD8 CTL expansion to a similar extent as 
wild type mice. Using the ovalbumin as surrogate antigen, alllogeneic 
tumor cells transfected with ovalbumin and gp96-Ig are able to mediate 
cognate CD8 CTL (OT-I) expansion to the same extent as syngeneic 
cells. Gp96-Ig deliverd by allogeneic tumor cells thus has many proper-
ties that make it suitable for vaccine purpose.
We have cotransfected the AD100 NSCLC line with HLA A1 and 
gp96-Ig. One million cells secrete 400ng gp96-Ig within 24h in tissue 
culture. Upon irradiation with 12,000 rad the cells continue to secrete 
gp96-Ig at declining rates for the next two weeks in culture. In the 
phase I study that has just opened we will enroll 24 patients with stage 
IIIB/IV NSCLC who have failed at least two lines of prior therapy. The 
vaccination schedule and analysis is similar to that described above for 
the B7 vaccine. Early results will be reported.
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Extensive stage small cell lung cancer (SCLC) is an incurable, aggres-
sive form of lung cancer with little improvement in outcome over the 
past 2 decades. SCLC tumor cells frequently express a mu-tant form 
of the p53 protein, which is far more stable than wild type p53, and 
therefore over-expressed. This differential over-expression as compared 
to normal cells provides the basis for the proposed tumor vaccine. The 
dependence of tumor cells on abnormal p53 expression for their sur-
vival makes this an “ideal” candidate for cancer immunotherapy, as the 
emergence of antigen-loss variants is not possible. We have developed 
a new vaccine based on transduction of dendritic cells (DC) with wild-
type p53 using an adenoviral construct. This vaccine demonstrated 
potency in pre-clinical experiments. Based on those observation we 
initiated a phase I/II clinical trial that was designed to test the safety 
and efﬁcacy of the Ad.p53-DC vaccine in patients who have extensive 
stage SCLC. 
Between January 2003 and June 2006, 54 patients with extensive stage 
small cell lung cancer were enrolled into trial. Patients were treated 
with platinum based ﬁrst-line chemotherapy to best response and those 
patients with stable disease or minor progression but retaining ECOG 
performance status of 0 or 1 underwent leukapheresis 8 weeks after the 
last dose of chemotherapy. DC were generated from peripheral blood 
precursors and then infected with adenoviral construct containing wild-
type p53 (ADVEXIN). The number of p53 positive DCs was evaluated 
using ﬂow cytometry. Patients received 3 doses of vaccine i.d. (2-5x106 
p53+ DCs per dose). If patients had stable disease or better, they were 
given 3 more doses of the vaccine monthly. 
No serious adverse events attributable to the vaccine occurred. No he-
matologic nor organ toxicity occured, and no autoimmunity developed. 
To evaluate immunological response, samples of peripheral blood were 
collected before immunization, 2-3 weeks after completion of 3 rounds 
of immunization and 2 months after completion of immunization. p53 
speciﬁc immune responses were evaluated in ELISPOT assay using ca-
narypox virus (ALVAC) containing wild-type p53 or empty vector us-
ing an automated ELISPOT reader (CTL). Response to vaccination was 
considered signiﬁcant if a p53-speciﬁc response after immunization 
(2-3 weeks after 3rd vaccine) was more than 2 SD higher than the p53-
speciﬁc response before immunization and at least 2 SD higher than the 
response to control ALVAC. Immune responses were further evalu-
ated in a subset of 12 HLA-A2 positive patients, using p53-derived or 
control peptides presented by HLA-A2. Signiﬁcant p53 speciﬁc T cell 
responses to vaccination were found in 41.9% of all treated patients. 
The pre-vaccination level of p53-speciﬁc immunity was similar in pa-
tients who responded immunologically to the vaccine to those who did 
not respond. We also analyzed the possible link between the number 
of DCs injected with each vaccine and p53 speciﬁc immune re-sponse 
developed as the result of immunization. No correlation between the 
number of injected DCs and p53-speciﬁc immune response was found. 
The level of anti-p53 antibody did not correlate with the development 
of p53-speciﬁc T-cell response or clinical response to vaccination. Anti-
adenovirus antibodies could potentially play a critical role in limiting 
the effectiveness of adenovirus based cancer vaccines. Most patients 
had a detectable pre-immunization level of anti-Adv IgG antibody. 
After three rounds of immunization with Adv-p53 DC, the titer of anti-
Adv antibody increased in 16 of 28 tested patients (57.1%). A moderate 
in-crease (>2 and <8 fold) was observed in 14 patients and a substantial 
(>8-fold) increase in 2 pa-tients. Both patients with the substantial in-
crease in anti-adenovirus antibodies did not develop p53-speciﬁc T-cell 
responses to immunization, wheares such were observed in 12 out of 14 
patients (85.7%) who had a moderately increased titer of anti-Adv anti-
bodies, and in only 5 out of 13 pa-tients (38.5%) who had no detectable 
increase in antibody titer (p = 0.018). The anti-adenovirus antibodies 
detected in those patients had neutralizing activity.
The generation of a p53-speciﬁc T-cell response depends not only on 
the quality of antigen stimulation but also on the functional activity of 
T-cells and antigen presenting cells in the host, speciﬁcally DCs. Our 
experiments demonstrated that immunological response to vaccination 
did not correlate with functional activity of DCs, T cells or the presence 
of regulatory T cells. Since myeloid derived suppressor cells (MDSC) 
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have been implicated in the immunosuppressive state of tumor-bearing 
hosts the SCLC patients were examined for the presence of these cells. 
Patients with SCLC had elevated level of MDSC prior to vaccina-
tion (p=0.01). After vaccination their presence increased even further 
(p=0.002). All patients with a normal level of MDSC prior to vaccina-
tion developed p53 speciﬁc immune responses to vaccination (100%), 
compared with only 4 out of 12 pa-tients who had an elevated level 
of MDSC (25.0%) (p=0.012). Thus, it appears that patients with an 
increased presence of MDSC were less likely to develop responses to 
vaccination compared to the patients with a normal level of MDSC. 
Two patients developed PRs that were directly attributable to the vac-
cine. Twelve patients had SD at re-staging performed 2 weeks after 
the third vaccine. Thirty-three of the patients who developed progres-
sive disease after the vaccine were treated with salvage chemotherapy. 
Seventeen (52%) patients had objective responses (3 CRs and 14 PRs). 
Twenty-two of these patients had platinum-resistant disease (progressed 
within 90 days of receiving a platinum containing regimen), and 10 of 
these patients (45%) responded to salvage chemotherapy (2 CRs and 
8 PRs). This observation is remarkable because the historic response 
rates to salvage chemotherapy in similar patient populations are 6%-
16%. Response to salvage chemotherapy correlated with the induction 
of a productive anti-p53 T cell response (p=0.025 in Fisher’s exact 
test). The median survival of all of the treated patients from the time 
of the ﬁrst vaccine administration was 8.8 months with 34% 1-year 
and 11% 2-year survivals. There was a clear trend toward signiﬁcance 
of a difference in median survivals of those patients who developed a 
productive anti-p53 speciﬁc T cell response (13.7 months) compared to 
those who did not (8.8 months) (p=0.13). 
Thus, Ad.p53 DC vaccine itself was safe, and produced major tumor 
responses in two patients. P53-speciﬁc T cell responses were induced 
by the vaccine in half of the treated patients. Our data demonstrated 
that the lack of immune response to vaccination was closely associated 
with accumu-lation of MDSC, previously shown to be immunosup-
pressive. However, the main ﬁndings from the trial were an unusually 
high frequency of major objective tumor regressions in patients treated 
with chemotherapy immediately after the vaccine. These observations 
were quite unexpected since the existing paradigm suggests that che-
motherapy is detrimental to the maintenance of an immune re-sponse. 
This suggests a possible new direction in cancer treatment where the 
combination of im-munotherapy and chemotherapy in direct sequence 
may provide substantial clinical beneﬁts. 
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Introduction
A renewed interest in cancer immunotherapy has been triggered by the 
identiﬁcation of tumor associated/speciﬁc antigens and the develop-
ment of therapeutic vaccines targeting these antigens. The mucinous 
transmembrane glycoprotein MUC1 is one such target. MUC1 is a 
heavily glycosylated integral membrane protein normally restricted to 
the apical surface of polarized epithelial cells, including those of the 
respiratory tract (1). The C-terminal domain contains a short extracel-
lular region, a transmembrane anchoring domain, and a 72 amino acid 
cytoplasmic tail.
MUC1 expressed on malignant cells differs from “normal” MUC1 in a 
number of important ways. In malignant cells MUC1 is over-expressed 
and loses its polarity of expression (2) such that it is expressed on 
the entire surface of the cell. In addition, the N-terminal ectodomain 
becomes under or aberrantly glycosylated, with truncated carbohydrate 
side chains. This results in exposure of the variable number tandem 
repeat regions of the peptide backbone to potential immune response.
Role of MUC1
The precise function of the MUC1 molecule remains undeﬁned in 
normal and malignant cells. Recent studies suggest MUC1 is involved 
in tumorigenicity, tumor cell migration, and resistance to stress-induced 
apoptosis and to chemotherapeutic agents (3-9). 
Over-expression of MUC1 in human carcinoma cells results a number 
of important changes including: elevated levels of stabilized, dephos-
phorylated, ß-catenin (3,4), attenuated intercellular levels of reactive 
oxygen species (6,7), and association of MUC1-CD with p53 (8), 
obstructing the p53-dependent apoptotic response. These changes may 
confer a survival advantage to malignant cells particularly under condi-
tions of oxidative or genotoxic stress. (6-9) 
The depolarized membrane distribution of MUC1 may facilitate inter-
action with stromal/endothelial ICAM-1, thereby promoting cell adhe-
sion and subsequent migration of tumor cells through the vasculature 
and ﬁbroblast-containing stroma (5).
High levels of serum MUC1 are associated with poor prognosis and 
immunosuppression in patients with advanced adenocarcinoma (10). 
MUC1 puriﬁed from ascitic ﬂuid of cancer patients suppresses T-cell 
proliferative response (11). There appears to be a failure to process and 
present soluble MUC1 on class II major histocompatibility complex 
(MHC), although it is readily taken up by dendritic cells (12). Conceiv-
ably, cells overexpressing tumor-associated MUC1 might escape a 
strong host immune response through this mechanism.
The altered expression of MUC1 on many epithelial cells, its multiple 
roles in cellular transformation, tumor cell migration, chemoresistance, 
and its immunosuppressive effects make this glycoprotein an attractive 
target for cancer immunotherapy.
Liposomal MUC1 Vaccine BLP25 (L-BLP25)
BLP25 liposome vaccine (L-BLP25) is a cancer vaccine strategy that 
targets the exposed core peptide of MUC1 tumor-associated antigen. L-
BLP25 consists of 3 essential components: the BLP25 lipopeptide, that 
provides the MUC1 antigen speciﬁcity; monophosphoryl lipid A (MPL), 
which acts as a non-speciﬁc immune stimulant; and a liposomal delivery 
system consisting of three lipids (cholesterol, dimyristoyl phosphatidyl-
glycerol, and dipalmitoyl phosphatidylcholine), which is felt to enhance 
delivery of the lipopeptide and MPL to immune-effector cells. 
Preclinical and Clinical L-BLP25 Studies
In preclinical murine studies, L-BLP25 induced a cellular immune 
response characterized by antigen-speciﬁc T-cell proliferation and 
production of interferon-γ (13), supporting the induction of a cellular 
immune response to the vaccine. This led to phase I and II clinical trials 
to assess its safety proﬁle and efﬁcacy. 
An initial phase I study in NSCLC patients showed that the vaccine 
could be administered with minimal toxicity (14). Two phase II trials 
established the dose and schedule of L-BLP25 and demonstrated the 
capability of the vaccine in eliciting a T-cell proliferative response in 
humans (15). The vaccine schedule established by these trials includes; 
a single dose of cyclophosphamide (300 mg/m2 to maximum 600 mg) 
given intravenously 3 days prior to start of vaccine; a primary vac-
